[1]严劼,胡竹林.改良结膜入路眼眶内下壁减压术治疗轻中度甲状腺相关眼病的临床效果[J].眼科新进展,2019,39(11):1067-1070.[doi:10.13389/j.cnki.rao.2019.0245]
　YAN Jie,HU Zhu-Lin.Clinical effects of refined transconjunctival inferomedial wall decompression surgery to treat mild to moderate thyroid-associated ophthalmopathy[J].Recent Advances in Ophthalmology,2019,39(11):1067-1070.[doi:10.13389/j.cnki.rao.2019.0245]
点击复制

改良结膜入路眼眶内下壁减压术治疗轻中度甲状腺相关眼病的临床效果/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年11期
页码:
1067-1070
栏目:
应用研究
出版日期:
2019-11-05

文章信息/Info

Title:
Clinical effects of refined transconjunctival inferomedial wall decompression surgery to treat mild to moderate thyroid-associated ophthalmopathy
作者:
严劼; 胡竹林
650021　云南省昆明市，昆明医科大学第四附属医院 昆明医科大学 云南省眼科研究所 云南省眼科疾病预防防治重点实验室 云南省第二人民医院白内障与眼底疾病防治省创新团队 云南省姚克专家工作站
Author(s):
YAN Jie; HU Zhu-Lin
Fourth Affiliated Hospital of Kunming Medical University，Kunming Medical University，Yunnan Eye Institute，Key Laboratory of Yunnan Province for the Prevention and Treatment of Ophthalmology，Provincial Innovation Team for Cataract and Ocular Fundus Disease，Expert Workstation of YAO Ke，Kunming 650021，Yunnan Province，China
关键词:
结膜入路内下壁眶减压术; 甲状腺相关眼病; 眼球突出度; 矫正
Keywords:
transconjunctival inferomedial wall decompression surgery; thyroid-associated ophthalmology; exophthalmos; rectification
分类号:
R777.5
DOI:
10.13389/j.cnki.rao.2019.0245
文献标志码:
A
摘要:
目的　评价改良结膜入路眼眶内下壁减压术治疗轻中度甲状腺相关眼病的疗效。方法　回顾性分析2017年1月至2018年8月在云南省第二人民医院行改良结膜入路眼眶内下壁减压术治疗的10例（11眼）轻中度甲状腺相关眼病患者。所有患者在术前均给予眼眶水平位、冠状位和矢状位CT检查，测量视力、眼球突出度、复视情况，检查眼外观进行眼前段照相等。将手术前、后眼球突出度，视力以及复视的改善情况作为效果评价指标，对相关数据进行统计和分析。结果　本组11眼术前眼球突出度为（18.94±1.40）mm，术后（15.22±1.46）mm；术后与术前比较，眼球突出度降低（3.72±0.64）mm，差异有统计学意义（t=18.379，P＜0.001）。术前视力为 0.53±0.29，术后为0.62±0.32；术后与术前比较，视力提高0.08±0.10，差异有统计学意义（t=-2.733，P=0.021）。术前复视2例；术后新发生复视2例，均为轻度复视。术前已存在复视的患者，术后复视程度无加重。结论　改良结膜入路眼眶内下壁减压术能有效改善甲状腺相关眼病患者的眼球突出度与视力，术后复视发生概率低，手术切口隐蔽美观，是一种可靠且有效的眶减压术式。
Abstract:
Objective　To evaluate the curative effect of refined transconjunctival inferomedial wall decompression to treat mild-moderate thyroid-associated ophthalmopathy (TAO).Methods　Totally 10 patients (11 eyes)with mild-moderate TAO from January 2017 to August 2018 in Yunnan Second People’s Hospital were retrospectively analyzed,who were received refined transconjunctival inferomedial wall decompression.All of patients were received orbital computed tomography in coronal,sagittal and horizontal positions and measurements including visual acuity,exophthalmos,diplopia,ocular appearance and anterior segment photography before operation.The improvements of exophthalmos,visual acuity and diplopia before and after operation were taken as evaluating indicators.The related data was counted and analyzed statistically.Results　The exophthalmos of 11 eyes was (18.94±1.40)mm before operation and (15.22±1.46)mm after operation.The reduction of exophthalmos was (3.72±0.64)mm,with statistically significant (t=18.379,P<0.001).The visual acuity was 0.53±0.29 before operation and 0.62±0.32 after operation.The visual acuity increased by 0.08±0.1,with statistically significant (t=-2.733,P=0.021).There were 2 patients with diplopia before operation and another 2 patients suffered from diplopia after operation,all of whom were mild diplopia.Diplopia did not exacerbate after operation in the 2 patients who had diplopia before operation.Conclusion　Refined transconjunctival inferomedial wall decompression can effectively improve exophthalmos and visual acuity with low rates of diplopia after operation,and the surgical incision is concealed and beautiful,so it is a reliable way for orbital decompression.

参考文献/References:

［1］　BARTALENA L，PINCHERA A，MARCOCCI C.Management of Graves’ ophthalmopathy：reality and perspectives［J］.Endocr Rev，2000，21（2）：168-199.
［2］　BARTALENA L，BALDESCHI L，DICKINSON A，ECKSTEIN A，KENDALL-TAYLOR P，MARCOCCI C，et al.Consensus statement of the European Group on Graves’ orbitopathy （EUGOGO） on management of GO［J］.Eur J Endocrinol，2008，158（3）：273-285.
［3］　BINGHAM C M，SIVAK-CALLCOTT J A，GURKA M J，NGUYEN J，HOGG J P，FELDON S E，et al.Axial globe position measurement：A prospective multicenter study by the international thyroid eye disease society［J］.Ophthalmic Plast Reconstr Surg，2016，32（2）：106-112.
［4］　SEGNI M，BARTLEY G B，GARRITY J A，BERGSTRALH E J，GORMAN C A.Comparability of proptosis measurements by different techniques［J］.Am J Ophthalmol，2002，133（6）：813-818.
［5］　NOVAES P，GRISOLIA A B D，SMITH T J.Update on thyroid-associated ophthalmopathy with a special emphasis on the ocular surface［J］.Clin Diabetes Endocrinol，2016，2（1）：19.
［6］　WEILER D L.Thyroid eye disease：a review［J］.Clin Exp Optom，2016，100（1）：20-25.
［7］　GUPTA S，DOUGLAS R.The pathophysiology of thyroid eye disease （TED）：Implications for immunotherapy［J］.Curr Opin Ophthalmol，2011，22（5）：385-390.
［8］　CUBUK M O，KONUK O，UNAL M.Orbital decompression surgery for the treatment of Graves’ophthalmopathy：comparison of different techniques and long-term results［J］.Int J Ophthalmol，2018，11（8）：1363-1370.
［9］　SUN M T，WU W，WATANABE A，KAKIZAKI H，CHEN B，UEDA K，et al.Orbital blowout fracture location in Japanese and Chinese patients［J］.Jpn J Ophthalmol，2015，59（1）：65-69.
［10］　COOK T.Evaluation and treatment of orbital fractures：A multidisciplinary approach［J］.Ophthalmic Plast Reconstr Surg，2007，23（3）：258-259.
［11］　BURM J S，CHUNG C H，OH S J.Pure orbital blowout fracture：new concepts and importance of medial orbital blowout fracture［J］.Plast Reconstr Surg，1999，103 （7）：1839-1849.
［12］　EUN S C，HEO C Y，BEAK R M，MINN K W，CHUNG C H，OH S J.Survey and review of blowout fractures［J］.J Korean Soc Plast Reconstr Surg，2007，34（5）：599-604.
［13］　WANG Y，YANG N，LI Y Y，XIAO L H.Multi-wall orbital decompression for disfiguring proptosis in patients with mild or moderate thyroid eye disease［J］.Zhonghua Yan Ke Za Zhi，2017，53（2）：128-135.
［14］　FELDING U.Blowout fractures-clinic，imaging and applied anatomy of the orbit［J］.Dan Med J，2018，65（3）：B5459.
［15］　KOTHARI N A，AVASHIA Y J，LEMELMAN B T，MIR H S，THALLER S R.Incisions for orbital floor exploration［J］.J Craniofac Surg，2012，23（7 Suppl 1）：1985.
［16］　FICHTER N，GUTHOFF R F，SCHITTKOWSKI M P.Orbital decompression in thyroid eye disease［J］.ISRN Ophthalmol，2012，2012：739236.
［17］　JR M C.Current trends in orbital decompression［J］.Ophthalmology，1985，92 （1）：21-33.
［18］　MAROON J C，KENNERDELL J S.Radical orbital decompression for severe dysthyroid exophthalmos［J］.Ophthalmology，1982，89（5）：467-472.
［19］　SANG U C，KIM K W，LEE J K.Surgical outcomes of balanced deep lateral and medial orbital wall decompression in Korean population：clinical and computed tomography-based analysis［J］.Korean J Ophthalmol，2016，30（2）：85-91.
［20］　GRAHAM S M，BROWN C L，RTER K D，SONG A，NERAD J A.Medial and lateral orbital wall surgery for balanced decompression in thyroid eye disease［J］.Laryngoscope，2003，113（7）：1206.
［21］　O’MALLEY M R，MEYER D R.Transconjunctival fat removal combined with conservative medial wall/floor orbital decompression for Graves orbitopathy［J］.Ophthalmic Plast Reconstr Surg，2009，25（3）：206.
［22］　GARRITY J A，FATOURECHI V，BERGSTRALH E J，BARTLEY G B，BEATTY C W，DESANTO L W，et al.Results of transantral orbital decompression in 428 patients with severe Graves’ ophthalmopathy［J］.Am J Ophthalmol，1993，116（5）：533-547.
［23］　CARTER K D，FRUEH B R，HESSBURG T P，MUSCH D C.Long-term efficacy of orbital decompression for compressive optic neuropathy of Graves’ eye disease［J］.Ophthalmology，1991，98（9）：1435.
［24］　SOARESWELCH C V，FATOURECHI V，BARTLEY G B，BEATTY C W，GORMAN C A，BAHN R S，et al.Optic neuropathy of Graves disease：results of transantral orbital decompression and long-term follow-up in 215 patients［J］.Am J Ophthalmol，2003，136（3）：433-441.
［25］　PERRY J D，KADAKIA A，FOSTER J A.Transcaruncular orbital decompression for dysthyroid optic neuropathy［J］.Ophthalmic Plast Reconstr Surg，2003，19（5）：353-358.
［26］　CHOE C H，CHO R I，ELNER V M.Comparison of lateral and medial orbital decompression for the treatment of compressive optic neuropathy in thyroid eye disease［J］.Ophthalmic Plast Reconstr Surg，2011，27（1）：4-11.
［27］　CHU E A，MILLER N R，LANE A P.Selective endoscopic decompression of the orbital apex for dysthyroid optic neuropathy［J］.Laryngoscope，2009，119（6）：1236-1240.
［28］　GORMAN C A，DESANTO L W，MACCARTY C S，RILEY F C.Optic neuropathy of graves’s disease.Treatment by transantral or transfrontal orbital decompression［J］.N Engl J Med，1974，290（2）：70.
［29］　BEN SIMON G J，SYED H R，SCHWARTZ R，GOLDBERG R A，MCCANN J D.Clinical manifestations and treatment outcome of optic neuropathy in thyroid-related orbitopathy［J］.Ophthalmic Surg Lasers Imaging，2006，37（4）：284-290.
［30］　KORKMAZ S，KONUK O.Surgical treatment of dysthyroid optic neuropathy：long-term visual outcomes with comparison of 2-wall versus 3-wall orbital decompression［J］.Curr Eye Res，2015，41（2）：1-6.
［31］　CRUZ A A，LEME V R.Orbital decompression：a comparison between trans-fornix/transcaruncular inferomedial and coronal inferomedial plus lateral approaches［J］.Ophthalmic Plast Reconstr Surg，2003，19（6）：440-445.
［32］　EING F，ABBUD C M，VELASCO E CRUZ A A.Cosmetic orbital inferomedial decompression：quantifying the risk of diplopia associated with extraocular muscle dimensions［J］.Ophthalmic Plast Reconstr Surg，2012，28（28）：204-207.
［33］　BOBORIDIS K G，UDDIN J，MIKROPOULOS D G，BUNCE C，MANGOURITSAS G，VOUDOURAGKAKI I C，et al.Critical appraisal on orbital decompression for thyroid eye disease：a systematic review and literature search［J］.Adv Ther，2015，32（7）：595-611.
［34］　LIU F，ZHU Y，ZHANG K，LI Z G.Effect of pulsed glucocorticoids combined with orbital radiotherapy for the treatment of severe active thyroid-associated ophthalmopathy［J］.J Xinxiang Med Univ，2016，33（7）：623-625.
刘芳，朱豫，张珂，李志刚.激素冲击联合放射治疗重度活动期甲状腺相关眼病疗效观察［J］.新乡医学院学报，2016，33（7）：623-625.
［35］　PARIDAENS D A，VERHOEFF K，BOUWENS D，VAN DEN BOSCH W A.Transconjunctival orbital decompression in Graves’ ophthalmopathy：lateral wall approach ab interno［J］.Br J Ophthalmol，2000，84（7）：775-781.
［36］　BAILEY K L，TOWER R N，DAILEY R A.Customized，single-incision，three-wall orbital decompression［J］.Ophthalmic Plast Reconstr Surg，2005，21（1）：1-9.
［37］　MCKEAG D，LANE C，LAZARUS J H，BALDESCHI L，BOBORIDIS K，DICKINSON A J，et al.Clinical features of dysthyroid optic neuropathy：a European Group on Graves’ Orbitopathy （EUGOGO） survey［J］.Br J Ophthalmol，2007，91 （4）：455-458.
［38］　NEIGEL J M，ROOTMAN J，BELKIN R I，NUGENT R A，DRANCE S M，BEATTIE C W，et al.Dysthyroid optic neuropathy.The crowded orbital apex syndrome［J］.Ophthalmology，1988，95（11）：1515.

相似文献/References:

[1]杨文娟 班胜刚 何剑峰.甲状腺相关眼病患者外周血单个核细胞中微小 RNA-146a的异常表达及意义[J].眼科新进展,2012,32(5):000.
[2]王方 朱豫 栗夏莲 明亮.甲状腺相关眼病患者血清中白细胞介素-15和白细胞介素-21的含量及临床意义[J].眼科新进展,2013,33(6):000.
[3]刘芳 朱豫 韩宝红.血清 sICAM-1及透明质酸与糖皮质激素治疗TAO敏感性关系的研究[J].眼科新进展,2012,32(2):000.
[4]刘振华 朱豫.甲状腺相关眼病患者血清可溶性细胞间黏附分子-1和可溶性血管细胞黏附分子-1的检测及临床意义[J].眼科新进展,2013,33(4):000.
[5]唐建,罗清礼. 瘦素基因在甲状腺相关眼病眶脂肪及体外分化眶脂肪细胞中的表达[J].眼科新进展,2014,34(9):801.[doi:10.13389/j.cnki.rao.2014.0222]
[6]金珂,朱豫. 甲状腺相关眼病患者干眼症患病率及特征分析[J].眼科新进展,2015,35(5):473.[doi:10.13389/j.cnki.rao.2015.0129]
　JIN Ke,ZHU Yu. Analysis of prevalence and characteristic of dry eye in patients with thyroid associated ophthalmopathy[J].Recent Advances in Ophthalmology,2015,35(11):473.[doi:10.13389/j.cnki.rao.2015.0129]
[7]欧阳明,刘桂琴,樊宁,等.小蘖碱对甲状腺相关眼病眼眶前脂肪细胞分化的影响[J].眼科新进展,2016,36(1):012.[doi:10.13389/j.cnki.rao.2016.0004]
　OU-YANG Ming,LIU Gui-Qin,FAN Ning,et al.Effects of berberine on differerntiation of orbital preadipocytes of TAO patients in vitro[J].Recent Advances in Ophthalmology,2016,36(11):012.[doi:10.13389/j.cnki.rao.2016.0004]
[8]何小寒,刘桂琴,蒋丽琼,等.甲状腺相关眼病患者和正常人眼眶脂肪组织中脂肪特异性磷脂酶A2的表达[J].眼科新进展,2016,36(9):841.[doi:10.13389/j.cnki.rao.2016.0225]
　HE Xiao-Han,LIU Gui-Qin,JIANG Li-Qiong,et al.Expression of AdPLA in orbital adipose tissue of normal and patients with thyroid associated ophthalmopathy[J].Recent Advances in Ophthalmology,2016,36(11):841.[doi:10.13389/j.cnki.rao.2016.0225]
[9]刘桂琴,欧阳明,王云,等.AdPLA 基因在Ⅲ级静止期甲状腺相关眼病眼眶脂肪内高表达研究[J].眼科新进展,2017,37(4):354.[doi:10.13389/j.cnki.rao.2017.0090]
　LIU Gui-Qin,OU-YANG Ming,WANG Yun,et al.Higher expression of AdPLA in orbital adipose tissue of patients with thyroid associated ophthalmopathy of Ⅲ level and stationary phase[J].Recent Advances in Ophthalmology,2017,37(11):354.[doi:10.13389/j.cnki.rao.2017.0090]
[10]严劼,李妍,胡竹林.不同治疗方法对改善甲状腺相关眼病症状的效果评价[J].眼科新进展,2019,39(8):758.[doi:10.13389/j.cnki.rao.2019.0173]
　YAN Jie,LI Yan,HU Zhu-Lin.The observation of different treatments for thyroid-associated ophthalmopathy[J].Recent Advances in Ophthalmology,2019,39(11):758.[doi:10.13389/j.cnki.rao.2019.0173]

备注/Memo

备注/Memo:
云南省眼科研究所、云南省眼科疾病研究重点实验室项目（编号：2017DG008）；院士和领军人才培养项目（编号：2017HC010）；院士专家工作站项目（编号：2017IC064）；云南省卫生科技计划项目（编号：2016NS182）；云南省重要眼表疾病预防和诊治新技术研究项目（编号：2018ZF009）
更新日期/Last Update: 2019-11-18